20-23364430-AC-A
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PVS1_StrongPM2PP5_Moderate
The NM_022482.5(GZF1):c.49delC(p.Leu17TyrfsTer17) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. L17L) has been classified as Benign.
Frequency
Consequence
NM_022482.5 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GZF1 | ENST00000338121.10 | c.49delC | p.Leu17TyrfsTer17 | frameshift_variant | Exon 2 of 6 | 1 | NM_022482.5 | ENSP00000338290.5 | ||
GZF1 | ENST00000377051.2 | c.49delC | p.Leu17TyrfsTer17 | frameshift_variant | Exon 1 of 5 | 1 | ENSP00000366250.2 | |||
GZF1 | ENST00000424216.1 | c.49delC | p.Leu17TyrfsTer17 | frameshift_variant | Exon 3 of 3 | 5 | ENSP00000410009.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with GZF1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Leu17Tyrfs*17) in the GZF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GZF1 are known to be pathogenic (PMID: 28475863). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.